International journal of antimicrobial agents · 2026
Optimising the meropenem dosing regimen in neonates: A dual-centre cohort study.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Zhang Tao, Cheng Hua, Han Xinyan, Du Qian, Chen Jiaojiao, Qiu Yulan, Wang Taotao, Dong Yalin
Аннотация
OBJECTIVE: To characterise meropenem pharmacokinetics in neonates and identify dosing regimens that optimize target attainment against common pathogens.
METHODS: This retrospective dual-centre cohort study analysed opportunistic meropenem plasma concentrations measured using a validated HPLC-MS/MS method. Neonates with severe renal impairment were excluded. A population pharmacokinetic model was developed and externally validated. Monte Carlo simulations were used to evaluate the probability of target attainment and cumulative fraction of response (CFR) for traditional simple/prolonged-infusion (TSPI) and optimised two-step administration therapy (OTAT) regimens.
RESULTS: The analysis included 114 neonates. A one-compartment model with first-order elimination best described the data. Body weight at admission (WT) was a significant covariate for both clearance (CL) and volume of distribution (Vd), while congenital heart disease (CHD) was a significant covariate for clearance. Typical CL and Vd were 0.175 L/h and 0.403 L, respectively. External validation showed satisfactory predictive performance. For the aggressive target (100% f T > MIC), TSPI often required high doses (≥ 30 mg/kg every 8 h). All evaluated OTAT regimens (20 mg/kg per dose every 8-12 h) were predicted to achieve CFR ≥ 90% for both targets across the evaluated pathogens. Simulated steady-state peak concentrations increased with the bolus fraction; therefore, the 5 mg/kg bolus followed by infusion of the remaining 15 mg/kg was selected as the preferred OTAT regimen to limit unnecessary peak exposure.
CONCLUSIONS: WT and CHD significantly influence meropenem pharmacokinetics in neonates. The 5 + 15 mg/kg OTAT regimen may provide a model-informed alternative to empirical dose escalation. Prospective clinical evaluation is warranted.
METHODS: This retrospective dual-centre cohort study analysed opportunistic meropenem plasma concentrations measured using a validated HPLC-MS/MS method. Neonates with severe renal impairment were excluded. A population pharmacokinetic model was developed and externally validated. Monte Carlo simulations were used to evaluate the probability of target attainment and cumulative fraction of response (CFR) for traditional simple/prolonged-infusion (TSPI) and optimised two-step administration therapy (OTAT) regimens.
RESULTS: The analysis included 114 neonates. A one-compartment model with first-order elimination best described the data. Body weight at admission (WT) was a significant covariate for both clearance (CL) and volume of distribution (Vd), while congenital heart disease (CHD) was a significant covariate for clearance. Typical CL and Vd were 0.175 L/h and 0.403 L, respectively. External validation showed satisfactory predictive performance. For the aggressive target (100% f T > MIC), TSPI often required high doses (≥ 30 mg/kg every 8 h). All evaluated OTAT regimens (20 mg/kg per dose every 8-12 h) were predicted to achieve CFR ≥ 90% for both targets across the evaluated pathogens. Simulated steady-state peak concentrations increased with the bolus fraction; therefore, the 5 mg/kg bolus followed by infusion of the remaining 15 mg/kg was selected as the preferred OTAT regimen to limit unnecessary peak exposure.
CONCLUSIONS: WT and CHD significantly influence meropenem pharmacokinetics in neonates. The 5 + 15 mg/kg OTAT regimen may provide a model-informed alternative to empirical dose escalation. Prospective clinical evaluation is warranted.